JAK1 and mature T-cell and NK-cell non-Hodgkin lymphoma: Recent findings showed proliferation and survival programs in ALCL-ALKneg and PTCL-NOS patients are driven by the presence of activating mutations on STAT3 or mutations involving other genes that secondarily activate STAT3 such as JAK1 or kinase fusions22.